Edition:
India

Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

4,616.85INR
2:28pm IST
Change (% chg)

Rs89.40 (+1.97%)
Prev Close
Rs4,527.45
Open
Rs4,530.70
Day's High
Rs4,629.05
Day's Low
Rs4,490.15
Volume
1,294,758
Avg. Vol
1,262,629
52-wk High
Rs4,670.00
52-wk Low
Rs2,351.20

Select another date:

Wed, Jul 1 2020

Photo

Fujifilm to partner with Dr. Reddy's to sell Avigan as COVID-19 treatment

TOKYO Japan's Fujifilm Holdings Corp announced a deal with India's Dr Reddy's Laboratories and Dubai-based Global Response Aid (GRA) to sell its anti-flu drug Avigan for COVID-19 treatment globally excluding Japan, China and Russia.

Fujifilm to partner with Dr. Reddy's to sell Avigan as COVID-19 treatment

TOKYO Japan's Fujifilm Holdings Corp announced a deal with India's Dr Reddy's Laboratories and Dubai-based Global Response Aid (GRA) to sell its anti-flu drug Avigan for COVID-19 treatment globally excluding Japan, China and Russia.

UPDATE 2-Fujifilm to partner with Dr. Reddy's to sell Avigan as COVID-19 treatment

TOKYO, July 1 Japan's Fujifilm Holdings Corp announced a deal with India's Dr Reddy's Laboratories and Dubai-based Global Response Aid (GRA) to sell its anti-flu drug Avigan for COVID-19 treatment globally excluding Japan, China and Russia.

Fujifilm to partner with Dr. Reddy's to sell Avigan overseas as COVID-19 treatment

TOKYO, July 1 Fujifilm Holdings Corp said on Wednesday it was partnering with Dr Reddy's Laboratories to sell the anti-flu drug Avigan in India and elsewhere to treat COVID-19, the respiratory disease caused by the coronavirus.

BRIEF-Dr.Reddy's Laboratories Says Launch Of Abiraterone Acetate Tablets In U.S. Market

* DR.REDDY'S LABORATORIES LTD SAYS LAUNCH OF ABIRATERONE ACETATE TABLETS USP, 250 MG IN U.S. MARKET. Source text for Eikon: Further company coverage:

BRIEF-Dr. Reddy's Laboratories Enters Into Licensing Agreement With Gilead Sciences For Remdesivir

* DR. REDDY'S LABORATORIES ENTERS INTO A LICENSING AGREEMENT WITH GILEAD SCIENCES FOR REMDESIVIR

BRIEF-Dr.Reddy's Labs Announces Launch Of Colchicine Tablets In U.S. Market

* ANNOUNCES LAUNCH OF COLCHICINE TABLETS USP, 0.6 MG IN U.S. MARKET Source text for Eikon: Further company coverage:

BRIEF-Dr.Reddy's Completes Acquisition Of Some Business Divisions Of Wockhardt

* COMPLETES ACQUISITION OF SELECT BUSINESS DIVISIONS OF WOCKHARDT Source text for Eikon: Further company coverage:

BRIEF-Midatech Pharma Enters Into Research Collaboration With Dr Reddy's

* MIDATECH PHARMA - ENTERED INTO A RESEARCH COLLABORATION WITH DR REDDY'S Source text for Eikon: Further company coverage:

BRIEF-Dr.Reddy's Labs Gets EIR From U.S. FDA For Medchal-Malkajgiri Facility

* INSPECTION CLASSIFICATION OF MEDCHAL-MALKAJGIRI FACILITY DETERMINED AS "NO ACTION INDICATED" Source text for Eikon: Further company coverage:

Select another date: